Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

ntrolled study of 446 patients at 44 international sites is designed to assess the TAXUS moderate-release paclitaxel-eluting coronary stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26 mm or greater in length and small vessels. Lesion size ranged from 18 - 40 mm in length and 2.5 - 3.75 mm in diameter. TAXUS VI is the first randomized, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years. Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularization (TLR, or retreatment rate) as compared to the bare-metal stent control group at four years. The four-year TLR rate was 12.9 percent for the TAXUS Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the TAXUS Stent group)). The rate of patients living free of TLR events was 87.1 percent at four years for the TAXUS Stent group, as compared to 78.6 percent for the bare-metal stent control group.

The four-year results for TAXUS VI support long-term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study. Even with an in vitro dosing rate 8-10 times greater than the commercialized slow-release formulation, no compromise in safety was observed. The TAXUS Stent group continues to report no new stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation TAXUS Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in 2003 and in the United States in 2004. The Company launched the slow-release formulation TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system in Europe and other international markets in 2005. The TAXUS Express modera
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Annual Meeting -, SAN FRANCISCO and EMERYVILLE, ... ) today announced results on the role of ... cancer and,osteoporosis. The data, which were presented at ... new regulatory elements are essential,for the differentiation of ...
... June 16 SuperGen Inc.,(Nasdaq: SUPG ... discovery, rapid,development and commercialization of therapies for ... the 13th Congress of the,European Hematology Association ... kinase inhibitor, prevents tumor cell proliferation in,vivo ...
Cached Medicine Technology:Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 2Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 3SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation 2
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... BRUNSWICK, N.J., Dec. 8 Savient Pharmaceuticals, Inc. (Nasdaq: ... Pharmaceuticals will be presenting at the upcoming 27th Annual J.P. Morgan ... presentation is scheduled to begin on Wednesday, January 14, 2009 at ... Westin St. Francis Hotel in San Francisco, CAJanuary 11-15, 2009. , ...
... Haemonetics announced today that Dr. Jonathan White will ... President of Haemonetics, effective December 8, 2008. In this ... of the next generation of products to complement Haemonetics, blood ... Brad Nutter, Haemonetics, Chairman and CEO, said, "As the global ...
... of the two-story,$35-millionHenry Ford II (West) Pavilion expansion project ... to 40 new private rooms complete,with wireless Internet access, ... to stay overnight. , ... investment in the Henry Ford,Hospital Campus. It will house ...
... Dec. 8 With its acclaimed debut in ... paper,patient medical records by bringing the process into ... far beyond basic record-keeping, allowing,subscribers to take charge ... their,records to use under their own centralized control ...
... Dec. 8 Triple-S,Management Corporation (NYSE: GTS ... announced that it has converted seven million issued and,outstanding ... in,conjunction with the expiration of the lockup agreements signed ... the Company,s initial public offering. It is,expected that the ...
... New Year,s is the most popular,time to try quitting smoking, ... that time resume smoking in less than one week.(1) ... of a New Year,s resolution,and may be well on their ... that smokers who use the 21 mg NicoDerm(R) CQ(R) nicotine ...
Cached Medicine News:Health News:Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th 2Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:$35 Million Henry Ford II Pavilion Expansion to Open 2Health News:$35 Million Henry Ford II Pavilion Expansion to Open 3Health News:$35 Million Henry Ford II Pavilion Expansion to Open 4Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 2Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 3Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 4Health News:Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program 2Health News:New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking 2Health News:New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking 3Health News:New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking 4
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: